SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)

A shareholder filed a securities class action against Aardvark Therapeutics (NASDAQ: AARD) on behalf of investors who bought shares in or traceable to its February 13, 2025 IPO, or during the February 13, 2025 to May 14, 2026 class period. The announcement creates litigation risk for Aardvark, though the release does not disclose specific allegations, claimed damages, or potential financial exposure.

Analysis

This is primarily a liquidity and governance overhang for AARD rather than a fundamental valuation signal. Plaintiff-firm announcements often precede additional claimant solicitation and can widen bid-ask spreads, discourage incremental long-only ownership, and create short-term volatility; without the complaint’s specific alleged omissions, damages theory, lead-plaintiff deadline, and insurance coverage, the expected cash liability cannot be underwritten. The near-term risk is therefore multiple compression from uncertainty rather than an immediately quantifiable earnings impact.

Over 1-3 months, the relevant catalyst is whether the underlying allegation is corroborated by a restatement, clinical/regulatory disclosure, guidance cut, insider-sales evidence, or a material corrective disclosure. Absent one of these, litigation headlines alone frequently fade after the lead-plaintiff process, particularly for small post-IPO issuers. Conversely, a weak cash position or need to raise capital would magnify the event: legal costs, a potentially higher cost of equity, and reduced financing flexibility could become more consequential than any eventual settlement.

The contrarian point is that a lawsuit notice is not evidence of merits and should not be treated as a standalone short catalyst after an initial reaction. The higher-probability opportunity is conditional: if shares decline materially while operating disclosures remain intact, resolution of the procedural phase may remove a technical overhang; if the complaint identifies previously undisclosed fundamental information, the risk shifts from legal noise to impaired intrinsic value.

Key Decisions for Investors

• Do not initiate a directional AARD position solely on this announcement; maintain a watch status until the filed complaint, alleged corrective disclosures, cash runway, and D&O insurance details are available.
• For existing long exposure, reduce position size or hedge over the next 1-3 months if AARD has near-term financing needs; litigation uncertainty can raise dilution risk even before damages are determined.
• Set an event alert for a restatement, clinical/regulatory setback, guidance revision, or financing announcement. Any of these would validate a fundamental short review; absent them, avoid chasing litigation-driven weakness.
• If AARD sells off sharply on lawsuit flow without a corresponding adverse operational disclosure, evaluate a small tactical long only after confirming liquidity and cash runway; invalidate the trade on a material correction to prior operating or development disclosures.